Tags

Type your tag names separated by a space and hit enter

Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice.
Pol J Pharmacol. 1993 Jul-Aug; 45(4):349-60.PJ

Abstract

Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, were studied in male Albino-Swiss mice. CGP 37849--at high doses only--increased the locomotor activity, while CGP 39551 decreased it. CGP 37849 and CGP 39551 did not change the locomotor activity, in monoamine-depleted mice (treated with reserpine + alpha-methyltyrosine). However, when administered together with clonidine, both those compounds produced a distinct hyperactivity. That antiakinetic effect was antagonized by haloperidol, but not by prazosin or idazoxan. In monoamine-depleted mice both the CGP compounds inhibited the locomotor hyperactivity evoked by apomorphine or L-DOPA (given jointly with benserazide). CGP 37849 antagonized the catalepsy evoked by fluphenazine, haloperidol, spiperone and reserpine. After CGP 39551 administration, a decreased muscle tension was observed, which rendered evaluation of the influence on catalepsy impossible. The obtained results (the antiakinetic effect, antagonized by haloperidol, and the anticataleptic effect) indicate that the NMDA receptor antagonists studied may act via an indirect activation of the dopamine system.

Authors+Show Affiliations

Institute of Pharmacology, Polish Academy of Sciences, Kraków.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7906989

Citation

Maj, J, et al. "Central Effects of CGP 37849 and CGP 39551, Competitive NMDA Receptor Antagonists, in Mice." Polish Journal of Pharmacology, vol. 45, no. 4, 1993, pp. 349-60.
Maj J, Rogóz Z, Skuza G. Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice. Pol J Pharmacol. 1993;45(4):349-60.
Maj, J., Rogóz, Z., & Skuza, G. (1993). Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice. Polish Journal of Pharmacology, 45(4), 349-60.
Maj J, Rogóz Z, Skuza G. Central Effects of CGP 37849 and CGP 39551, Competitive NMDA Receptor Antagonists, in Mice. Pol J Pharmacol. 1993 Jul-Aug;45(4):349-60. PubMed PMID: 7906989.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice. AU - Maj,J, AU - Rogóz,Z, AU - Skuza,G, PY - 1993/7/1/pubmed PY - 1993/7/1/medline PY - 1993/7/1/entrez SP - 349 EP - 60 JF - Polish journal of pharmacology JO - Pol J Pharmacol VL - 45 IS - 4 N2 - Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, were studied in male Albino-Swiss mice. CGP 37849--at high doses only--increased the locomotor activity, while CGP 39551 decreased it. CGP 37849 and CGP 39551 did not change the locomotor activity, in monoamine-depleted mice (treated with reserpine + alpha-methyltyrosine). However, when administered together with clonidine, both those compounds produced a distinct hyperactivity. That antiakinetic effect was antagonized by haloperidol, but not by prazosin or idazoxan. In monoamine-depleted mice both the CGP compounds inhibited the locomotor hyperactivity evoked by apomorphine or L-DOPA (given jointly with benserazide). CGP 37849 antagonized the catalepsy evoked by fluphenazine, haloperidol, spiperone and reserpine. After CGP 39551 administration, a decreased muscle tension was observed, which rendered evaluation of the influence on catalepsy impossible. The obtained results (the antiakinetic effect, antagonized by haloperidol, and the anticataleptic effect) indicate that the NMDA receptor antagonists studied may act via an indirect activation of the dopamine system. SN - 1230-6002 UR - https://www.unboundmedicine.com/medline/citation/7906989/Central_effects_of_CGP_37849_and_CGP_39551_competitive_NMDA_receptor_antagonists_in_mice_ DB - PRIME DP - Unbound Medicine ER -